Company intelligence / Profile preview
Yungjin Pharmaceutical
Seoul, Korea, Republic Ofeng.yungjin.co.kr ↗
- Ownership
- Public · KRX:003520
- Employees
- ~500
- Development stage
- Other
01
Overview
Yungjin Pharmaceutical has a diverse pipeline targeting major indications, including a lead natural product (YPL-001) for COPD in Phase 2 development (FDA/US), with numerous generics and branded drugs marketed for CNS, anti-infective, cardiovascular, metabolic, and inflammatory diseases. YPL-001 demonstrates a novel anti-inflammatory mechanism and is positioned for COPD patients with steroid resistance[4][2].
- Therapeutic areas
- CardiovascularPulmonologyNeurologyInfectious DiseasesPsychiatry
- Modalities
- Small moleculeNatural productBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
KT&G groupPotential out-licensing/co-development partners for YPL-001
04
Financials
- Market cap
- $111.6M
- Total revenue
- $187.8M
- Enterprise value
- $166M
Beyond the preview
Go deeper on Yungjin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yungjin Pharmaceutical.